ARTICLE | Clinical News
MGCD290: Phase I data
November 5, 2012 8:00 AM UTC
Data from 4 double-blind, placebo-controlled Phase I trials showed that single and multiple ascending-doses of once-daily MGCD290 were generally well tolerated with no serious adverse events reported....